Immunocompromised participants were much more likely to have received at least four doses of COVID-19 vaccine than their ...

Pearl Diagnostics will receive $1 million to evaluate the potential of a prototype assay for early detection of pneumonia caused by Pseudomonas aeruginosa.

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

Antimicrobial resistance is a growing health crisis that could lead to millions of deaths by 2050, according to the World ...

Photodynamic inactivation using curcumin shows promise in reducing antibiotic resistance diversity in Staphylococcus aureus, ...

Diarrheagenic E. coli (DEC) is a major global cause of diarrheal diseases, with certain strains showing alarming levels of antibiotic resistance.

By combining MERFISH imaging with expansion microscopy, researchers have unlocked a new way to study bacteria at the ...

An antibiotic used to treat infective diarrhea could be an effective drug for a type of inflammatory bowel disease, a new ...

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

When managing an irritated cornea, choosing among fortified antibiotics, oral antivirals, anti-inflammatories or combination ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...